A key component of Silence's business strategy is the establishment of additional high-value partnerships with the leading pharmaceutical companies.

Silence believes that the company's comprehensive RNAi therapeutic platform can support and advance multiple partnerships with the pharmaceutical industry across a diverse range of therapeutic opportunities. In particular, the company's broad range of complementary siRNA delivery technologies allows Silence to offer potential partners a choice of solutions for the delivery of RNAi molecules to diseased tissue - one of the main challenges in the emerging field of RNAi therapeutics.

The company's unique RNAi therapeutic platform has drawn the attention of many leading pharmaceutical companies worldwide and Silence is actively engaged in partnering discussions spanning a range of new and exciting development opportunities.

For more information on outlicensing or partnering opportunities, please contact: